Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise

(2014) D. A. Proia et al.   CANCER RESEARCH

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

(2014) Susann Weissmueller et al.   CELL

Targeting tumour-supportive cellular machineries in anticancer drug development

(2014) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib

(2014) H Landmann et al.   Cell Death & Disease

Histone deacetylase inhibitors

(2013) Marije Slingerland et al.   ANTI-CANCER DRUGS

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

(2013) W Hanel et al.   CELL DEATH AND DIFFERENTIATION

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer

(2013) M. A. Socinski et al.   CLINICAL CANCER RESEARCH

Geldanamycin and its derivatives as Hsp90 inhibitors

(2012) Magdalena Gorska   Frontiers in Bioscience-Landmark

Drastic Effect of GermlineTP53Missense Mutations in Li-Fraumeni Patients

(2012) Yasmine Zerdoumi et al.   HUMAN MUTATION

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones

(2011) David Siegel et al.   BIOCHEMICAL PHARMACOLOGY

Multiple Stress Signals Activate Mutant p53 In Vivo

(2011) Y.-A. Suh et al.   CANCER RESEARCH

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

(2011) David A. Proia et al.   PLoS One

p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma

(2010) Brendan Doyle et al.   JOURNAL OF PATHOLOGY

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

(2010) Andelko Hrzenjak et al.   Molecular Cancer

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

(2009) J. P. Morton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT